How BiltRx works, what it costs, and what the fine print changes
This scope is intentionally narrow. BiltRx markets many wellness, aesthetics, supplement, and general-care services, but only clinician-directed GLP-1, hormone, longevity, peptide, sexual-health, and hair-loss offerings are evaluated here.
BiltRx Inc. owns the platform and expressly says it is not the healthcare provider. Its formal terms name Bask Health and OpenLoop as medical groups. Their physicians and allied health professionals independently control diagnosis, prescribing, and treatment.
The public office is in Houston. The about page attributes the company to Joe Duarte and Dr. Nishant Rao and describes a fully remote clinic. Those are first-party identity claims; they do not by themselves verify every treating clinician, license, or dispensing relationship.
A current FAQ states that a $9.99 monthly membership includes care coordination, priority support, and supplement savings, while consultation and medication are billed separately. Current product pages also say consultation and shipping apply separately.
The formal terms describe a different checkout presentation: one total subscription price that can include platform use, a pharmacy drug charge, and a medical-group fee. Because the public pages do not reconcile this with the FAQ or quantify consultation and shipping, the draft cannot promise an all-in monthly total.
Each compact card adds the stated $9.99 recurring membership to the current product amount. When multiple current brands or formulations share one ingredient and route, their monthly product amounts are averaged first. Unpriced consultation, shipping, taxes, and any checkout adjustment remain disclosed as additional fees.
The semaglutide injection card combines compounded semaglutide at $81, Ozempic at $1,449, and Wegovy at $1,849. The product mean is $1,126.33; adding membership gives $1,136.32, displayed as Avg. $1,136/mo + fees. Compounded and approved products remain clinically and regulatorily distinct even though the ingredient and route are consolidated.
The tirzepatide injection card combines compounded tirzepatide at $129, Mounjaro at $1,499, and Zepbound at $1,499. The product mean is $1,042.33; adding membership gives $1,052.32, displayed as Avg. $1,052/mo + fees.
Older first-party cards and a separate store show much higher compounded GLP-1 prices, including $299 for semaglutide and $699 for tirzepatide. A tirzepatide oral-dissolving tablet is also sold in the store, but the page does not establish approved efficacy or an FDA-reviewed dosage form. It remains editorial-only.
BiltRx correctly labels its compounded semaglutide and tirzepatide products as not FDA approved. FDA explains that compounded drugs are not reviewed for safety, effectiveness, or quality before marketing and that semaglutide and tirzepatide compounding is constrained by current shortage and copy rules. The exact pharmacy, formula, concentration, and lawful patient-specific basis must be confirmed.
The Mounjaro page says the product is FDA approved for both type 2 diabetes and weight loss. Current FDA labeling identifies Mounjaro for glycemic control in type 2 diabetes, while Zepbound is the tirzepatide brand approved for chronic weight management. Weight use of Mounjaro is off-label.
The two TRT cards use current dedicated-page amounts: $65 for testosterone cypionate injection and $97 for testosterone Lipoderm cream, plus membership. The older hormone category lists testosterone cypionate from $50. Both dedicated pages limit the program to patients age 25 or older in a named set of states and require baseline and follow-up labs.
BiltRx's hormone category also lists enclomiphene, gonadorelin, estradiol, progesterone, and nonhormonal options. Their linked detail destinations currently resolve to the home page, and several flat rates do not state duration or exact dosage form. They remain editorial-only rather than inflating the therapy count.
Five longevity and peptide cards cover glutathione injection, cobalamin injection, NAD+ injection, subcutaneous sermorelin, and subcutaneous tesamorelin. Nasal sprays, NAD+ cream, and nutrient blends are listed as alternatives in the narrative, not as additional therapies.
The glutathione page permits intramuscular or intravenous administration, the B12 page identifies only cobalamin rather than a specific form, and the NAD+ page permits intramuscular or subcutaneous use. Those identities are retained as ambiguous and cannot be matched to a route-specific AllyRx medication record.
Sermorelin is marketed for wellness and anti-aging, uses a subcutaneous injection, and is not FDA approved for those purposes. Tesamorelin is FDA approved for reducing excess abdominal fat in adults with HIV and lipodystrophy, not for general weight loss or anti-aging. BiltRx's broader tesamorelin positioning is off-label.
The PT-141 page identifies bremelanotide and a subcutaneous route but does not establish that the supplied product is the FDA-approved Vyleesi auto-injector. The page simultaneously describes a limited approved use and ends with a not-FDA-approved compounded-product disclaimer. The card is therefore unmapped and comparison-disabled.
Sildenafil and Viagra are one ingredient-and-oral-route card. Their $84 and $535 product amounts average $309.50; membership produces $319.49, displayed as Avg. $319/mo + fees. The page allows standard tablets or compounded chewables, so the exact dosage form must be confirmed. Tadalafil remains a separate oral ingredient.
Topical minoxidil solution and foam are consolidated as one topical ingredient record. Oral minoxidil appears only in explanatory copy and does not become another card. Finasteride is a distinct oral tablet card. Quantities and strengths are not published for either current price.
The general flow is account creation, health intake, licensed-provider review, and delivery when prescribed. Current pages use phone, video, and online-consultation language. The exact synchronous or asynchronous encounter, follow-up cadence, and clinician type must be confirmed for the selected program.
Availability is product specific. The public state map links all states but does not prove that every treatment is available in each. The current TRT pages publish a narrower list of 32 states plus Washington, DC, and add an in-person laboratory requirement for patients in New York.
Formal terms name Labcorp and myLAB Box and say laboratory products ordered through the platform are fulfilled only through named labs, with their cost included in the platform total. TRT pages instead describe an approved local lab. The actual lab path and price should be confirmed before checkout.
Pharmacy identity is inconsistent. Formal terms name GoGo Meds and Tailor Made Compounding Pharmacy and authorize transfers between pharmacies without notice. The home-page FAQ instead names Southend Pharmacy and Boothwyn Pharmacy. Current product pages also reference Partell Specialty Pharmacy for some compounded products.
The public FAQ says prescriptions are usually processed in one to three business days and received three to seven business days after approval. Formal terms make delivery dates estimates, allow separate shipping and handling charges, and shift risk of loss when the product reaches the carrier.
Subscriptions renew automatically. The first renewal may be early, and later charges or shipments can occur up to two days early. Formal terms require cancellation at least two days before renewal by email, phone, or online account; the FAQ refers to a one-day restriction, so the two-day formal cutoff is the safer rule.
Partial-period refunds are not ordinarily offered, though BiltRx reserves case-by-case discretion. Orders cannot be canceled after a licensed provider approves the prescription. Product availability, taxes, shipping, and corrected pricing can change the final amount.
The service is primarily cash pay. Formal terms say BiltRx and its medical groups do not bill federal or state healthcare programs. A separate marketing flow offers to check insurance coverage for branded GLP-1 drugs, but coverage, prior authorization, and reimbursement are never guaranteed.
The terms say BiltRx is not itself a HIPAA covered entity, while named clinical, laboratory, or pharmacy parties may be covered entities or business associates. A separate notice says BiltRx and affiliated providers comply with HIPAA. Patients should distinguish platform account data from protected information used for treatment, laboratory, or pharmacy services.
Awin program 115383 remains pending. The commission rate is undisclosed, attribution is listed as 30 days, and direct linking from paid ads requires express advertiser approval. No tracking URL or customer offer is approved, so the CTA remains an ordinary nofollow link and affiliate economics do not affect the rating.
- Fourteen cards consolidate distinct ingredients and routes without counting brands, strengths, or marketing names as therapies.
- Every compact price includes the published $9.99 monthly membership, while unpriced consultation and shipping stay outside the headline.
- All cards remain comparison-disabled because the public pages do not establish a stable all-in total.
- Current and older first-party pages materially disagree on several compounded GLP-1, peptide, and longevity prices.
- The formal terms and home page name different dispensing pharmacies.
- Mounjaro's weight-loss approval claim and PT-141's FDA-status language require correction or clarification.
- TRT has the clearest clinical guardrails, including age, state, baseline-lab, and monitoring requirements.
- Women's HRT, enclomiphene, and gonadorelin remain editorial-only because their linked detail pages are not live and the public rates lack complete supply terms.